Clinical trial · Interventional
Immunotherapy and Paraneoplastic Neurological Syndromes
Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Paraneoplastic Neurological Syndromes (PNS) are rare remote effects of cancer, not directly attributed to mass lesions, metastases, infections, ischemia, coagulopathy, metabolic disruptions or tumour treatment. Currently, PNS treatment is mostly limited to tumour treatment. Because of an initial inflammatory stage early in the evolution of the PNS several immunotherapy modalities have been tried. Intravenous human immunoglobulins could be expected to provide a stabilization or even improvement of PNS, if administered early enough to prevent permanent neuronal damage.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Paraneoplastic Neurological Syndromes | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunoglobulin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- immunoglobulin
- interventionNames
- Drug: Immunoglobulin
Primary outcomes (1)
- measure
- percentage of patients with neurological improvement after 3 months of immunotherapy with IVIg
- timeFrame
- 3 months
- description
- "Success" is defined by ≥ 1 point lower score in the modified Rankin Scale (mRS) after treatment compared to baseline. "Failure" is defined by failure to meet the success definition.
Secondary outcomes (8)
- measure
- percentage of patients with neurological improvement after 6 months of immunotherapy with IVIg
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria : * Age ≥ 18 years * Clinical diagnosis of PNS according to published criteria * Positive well-characterized onconeural antibodies (Hu, Yo, CV2/CRMP5) in serum or CSF samples * Rankin score between 2 and 4 * Less than 6 months since onset of symptoms * Less than 3 weeks in a Rankin score between 2 and 3 * Patients who have given written informed consent Exclusion criteria : * Patients not be able to receive IVIg * Patients who receive or will receive concomitant immunotherapy different from that in the protocol * Patients with known selective deficiency of IgA * Women of childbearing potential who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions * Patients with psychiatric or systemic diseases that prevent the proposed treatment * Patients who will not be able to attend the required follow-up visits * Renal, hepatic or cardiac insufficiency, coagulopathy
References
Publications (1)
- DERIVEDBerzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanche JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):789-792. doi: 10.1136/jnnp-2017-316904. Epub 2017 Oct 30. No abstract available. PMID 29084869